31 results about "Cell cancer" patented technology

The invention discloses a cell line for lowly-metastatic clear cell carcinoma of kidney of Han Chinese, namely LoMeT-ccRcc CCTCC No.C200910. The cell line can grow for a long time in vitro and be stably handed down, has epithelioid cell form, and has no contact inhibition. The cell is heteroploid, chromosome number and structure are aberrant. Immunohistochemistry shows masculine CA9 and CD133. A flow cytometry analyses and finds out that CA9 and CD133 expression is obviously enhanced in the condition that cell is handed down for many times. The cell line has lowly-metastatic trend after the cell is handed down continuously. The recovery rate of the cell line after being frozen is more than 80%, the recovered cell growth state accords with the original cell. The cell line of the invention is used for establishing a cell model for sieving and preparing medicines that is used for dialogising, preventing and treating clear cell carcinoma of kidney.

The present invention relates to a screening method for classifying patients and for selecting an effective chemotherapy for the treatment of a patient suffering from non-small-cell lung cancer (NSCLC), based on the use of his levels of BRCA1 expression to predict the outcome of chemotherapy.

The invention relates to an application of an RNA (Ribose Nucleic Acid) polymerase II fifth subunit regulatory protein (RMP) in preparation of a reagent for prognosis of hepatocellular carcinoma or auxiliary TACE (Transcatheter Arterial Chemoembolization). The invention firstly reveals that high expression of the RMP in a hepatic cell cancer indicates unsatisfactory prognosis of resection of hepatocellular carcinoma after operation; meanwhile, the high expression of the RMP further indicates that the auxiliary TACE after operation is effective. Thus, the invention establishes an RMP-based prognosis method of the hepatic cell cancer after operation.

The invention belongs to the field of analytical chemistry and clinical medicine and relates to a plasma metabolization micromolecule marker related to the human non-small-cell lung cancer and an application of the plasma metabolization micromolecule marker. The plasma metabolization micromolecule marker related to the human non-small-cell lung cancer is one or more of cortisol, corticosterone and 4-methoxyphenylacetic acid. The plasma metabolization micromolecule marker is prepared from cortisol, corticosterone and 4-methoxyphenylacetic acid. The content range (95% confidence interval) of cortisol is 0.00018-0.00067, the content range (95% confidence interval) of corticosterone is 0.000029-0.00010, the content range (95% confidence interval) of 4-methoxyphenylacetic acid is 0.000015-0.000022, and metabolite can prompt occurrence of tumors within the ranges. The horizontal range, corresponding to a normal group, of cortisol is 0.0030-0.0037, the horizontal range, corresponding to the normal group, of corticosterone is 0.00044-0.00056, and the horizontal range, corresponding to the normal group, of 4-methoxyphenylacetic acid is 7.39 E-07-2.09 E-06. The plasma metabolization micromolecule marker is a novel biomarker, compared with a traditional protein biomarker, the relevance between the marker and the disease outcome is higher, and the plasma metabolization micromolecule marker is stable, minimally invasive, easy to detect and accurate in quantitation.

A relationship between cancer and ribonucleic acid (RNA) regulation is described by determining intracellular levels of niRN A regulators. Generally, mRNA levels are decreased in cancer cells that may be a reflection of either reduced mRNA expression and / or increased mRNA degradation. miRNAs are identified that hybridize to an mRNA that are suspected to mediate intracellular mRNA steady state levels. Alternatively, ribonucleic acid binding protein (RBP) levels may also mediate intracellular mRNA steady state levels. In particular, this invention demonstrates an effective clinical management strategy for uterine cell cancers may be implemented by taking advantage of an exemplary relationship between P2X7 mRNA and miRNAs including, but not limited to, miR-186 and / or miR-150.

This invention relates to an antitumor agent comprising carboplatin and a combination drug of tegafur / gimeracil / oteracil potassium to be administered to a cancer patient selected according to an expression level of thymidylate synthase gene.

The present invention provides a combination therapy comprising the compound 4-[4-[4-(4-fluoro-3-trifluoromethyl-phenyl)-1-methyl-1H-imidazol-2-yl]-piperidin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine, or a pharmaceutically acceptable salt thereof, and an mTOR inhibitor for use in the treatment of glioblastoma multiforme, adenocarcinomas of the colon, non-small-cell lung cancer, small-cell lung cancer, cisplatin-resistant small-cell lung cancer, ovarian cancer, leukemia, pancreatic cancer, prostate cancer, mammary carcinoma, renal cell carcimoma, multiple myeloma, Kaposis Sarcoma, Hodgkins lymphoma, lymphangioleiomyomatosis, Non-Hodgkins lymphoma or sarcoma.

The invention discloses a DNA fragment for peculiarly inhibiting Rab27B gene expression and the application thereof. A small interfering RNA provided by the invention is of a double-stranded RNA consisting of nucleotide sequences indicated by sequences 4 and 5 in a sequence table. The DNA fragment is shown in formula I, and SEQ forward nucleotide sequence is shown as sequence 2 in the sequence table; the SEQ reverse is complementary with the SEQ forward in opposite directions; and X is of an intron. The experiment approves that: when the DNA fragment is introduced to hepatic cell cancer cell, the Rab27B expressed protein is remarkably reduced, and the vitro proliferation capacity, vitro adhesion capacity, vitro migration capacity and vitro invasive capacity of HCC97H cell are remarkably reduced after the Rab27B is reduced. SEQ FORWARD - X - SEQ REVERSE (I).

The invention relates to a novel selective cyclooxygenase-2 inhibitor compound, a preparation method and use and belongs to the field of chemical drugs. The compound represented by a formula (I) shown in the description can be used for inhibiting cyclooxygenase and interfering with the biotransformation of in-vivo arachidonic acid to prostaglandin, so that the compound and pharmaceutical compositions thereof can be used for treating cyclooxygenase mediated related diseases, i.e., can be used for treating and relieving animal and human inflammations and inflammation caused various diseases such as arthritis, neurodegenerative disease, depression, schizophrenia disease and cancers (including non-small-cell lung cancer, liver cancer, pancreatic cancer, colon cancer, breast cancer, ovarian cancer, prostatic cancer, cervical cancer, skin cancer, head and neck cancer and the like).

The present invention provides a compound 4-[4-[4-(4-fluoro-3-trifluoromethyl-phenyl)-1-methyl-1H-imidazol-2-yl]-piperidine-1- combination therapy of ]-1H-pyrazolo[3,4-d]pyrimidine or a pharmaceutically acceptable salt thereof and an mTOR inhibitor for the treatment of glioblastoma multiforme, colon adenocarcinoma, non-small cell lung cancer , small cell lung cancer, cisplatin-resistant small cell lung cancer, ovarian cancer, leukemia, pancreatic cancer, prostate cancer, breast cancer, renal cell carcinoma, multiple myeloma, Kaposi's sarcoma, Hodgkin's lymphoma, Lymphangioleiomyoma, non-Hodgkin lymphoma, or sarcoma.

The invention relates to the technical field of medical biology engineering, in particular to a dendritic cell vaccine and a preparation method and application of the dendritic cell vaccine. Disclosed is a method for preparing a dendritic cell (DC) cancer vaccine for persons with liver cancer stem cells. The method comprises the following steps of inserting Oct4 and Sox2 genes in an AAVSl locus of a hepatoma cell line genome by using a zinc finger nuclease technology; enriching similar liver cancer stem cells in corrected liver cancer cells by using a tumor stem cell spheroid forming method; and separating prepared dendritic cells by stimulating autologous blood through similar liver cancer stem cell freeze thawing and cracking liquid to obtain antigen presentation DC cells loaded with liver cancer stem cell antigens. Established liver cancer stem cell strains can express molecular markers of the liver cancer stem cells at a high level, expression of a plurality of liver cancer stem cell markers such as CDl3, CD90, EpCAM and the like can be improved obviously, and the specificity is high; the used antigen presentation dendritic cells source from the autologous blood, are high in safety and have little toxic and side effects; and after being tried out, the prepared DC cell cancer vaccine can obviously stimulate CTL (cytotoxic T lymphocyte ) reaction of the specificity cell toxic effect of the tumor stem cells.